Competitive inhibitors of the salvage pathway enzyme purine-nucleoside phosphorylase (purinenucleoside:orthophosphate ribosyltransferase, EC 2.4.2.1) have been designed by using the three-dimensional strucre of the enzyme as determined by x-ray crystallography. 
The concept of drug design based on crystallographic and modeling methods has received much attention, yet few solid examples have appeared in the literature. Two notable exceptions are the reports by Erickson et al. (1) on the design of human immunodeficiency virus protease inhibitors and Appelt et al. (29) on the design of thymidylate synthase inhibitors. Advances in crystallography, computer graphics, and related fields have resulted in a dramatic increase in the number of macromolecular structure determinations while advances in computer hardware and computational methods have allowed the computational chemist to address more complex problems with higher accuracy (2, 3) . Clearly, structural information combined with graphical methods for depicting the accessible volume, electrostatic potential, and active-site hydrophobicity aids drug design. Further enhancement in the quality of the "designed compounds" is expected from methods that can accurately evaluate the target molecule in terms of binding conformation, binding affinity, and binding-induced changes in protein conformation. We have developed Monte Carlo-based conformational search methods that, in combination with energy minimization, accurately predict the crystallographically observed ligand binding conformations for enzyme-inhibitor complexes. We now report the use of crystallographic and modeling methods for the design of competitive inhibitors of the enzyme purine nucleoside phosphorylase (PNP; purine nucleoside:orthophosphate ribosyltransferase, EC 2.4.2.1).1 PNP as a Target for Drug Design. PNP catalyzes the reversible phosphorolysis of purine ribo-or 2'-deoxyribonucleosides to the purine and ribose-or 2-deoxyribose-a-1-phosphate. The enzyme has been isolated from both eukaryotic and prokaryotic organisms (4) and functions in the purine salvage pathway (5, 6) . PNP isolated from human erythrocytes is specific for the 6-oxypurines and many of their analogs (7) , while PNPs from other organisms vary in their specificity (8) . The human enzyme is a trimer with identical subunits and a total molecular mass of --97 kDa (9, 10) .
Interest in PNP as a drug target arises from its ability to rapidly metabolize purine nucleosides and from its role in the T-cell branch of the immune system. The chemotherapeutic potential ofpurine nucleoside analogs such as the 6-thiopurine 2'-deoxyribonucleosides (11) and 2',3'-dideoxyinosine (12) may be severely compromised by PNP metabolism. Hence, a combination of a PNP inhibitor with these compounds may be highly efficacious. Administered alone, PNP inhibitors have potential therapeutic value since children lacking PNP activity exhibit severe T-cell immunodeficiency while maintaining normal B-cell function (13) . This profile suggests utility for PNP inhibitors in the treatment of T-cell leukemias or lymphomas, in organ transplantation, and in T-cell-mediated autoimmune diseases such as rheumatoid arthritis and lupus. Despite the potential benefits ofPNP inhibitors and despite the large number of PNP inhibitors that have been synthesized to date (4, 14) , no compound has yet reached clinical trials. Although potencies for the best compounds have affinities 10-100 times higher than the natural substrate (K.1, 4O pM), it is expected that T-cell immunotoxicity will require very tight binding inhibitors (K;, <10 nM) due to the high in vivo PNP activity and competition with substrate (15) . Hence, we determined the structure of human PNP (Fig. 1 ) by x-ray crystallography (16) and have used these results in combination with computer-assisted molecular modeling to design highly potent inhibitors of this key enzyme.
Overall Strategy for Inhibitor Design. Once the structure of PNP was known, a scheme was used that involved both inhibition data and x-ray crystallography for evaluation ofthe synthesized compounds and a combination of these data and molecular modeling for the design of the next round oftarget molecules. A flow chart describing the overall strategy is shown in Fig. 2 . Proposed compounds were screened by modeling the enzyme-inhibitor complex by using interactive computer graphics (17) and AMBER (18, 19) The phosphate binding site, composed of residues Ser-33, Arg-84, His-86, and Ser-220, is located near a glycine-rich loop (residues 32-37) with the phosphate positioned for nucleophilic attack at atom C(1') of the nucleoside. The ribose binding site is largely hydrophobic and contains a hydrogen bonding group, Tyr-88, which interacts with the 0(3') position. The residue nearest 0(2') is Met-219 and the residue nearest 0(5') is His-86. One side ofthe ribose binding site contains several aromatic amino acids including Phe-159, Phe-200, His-86, and Tyr-88. This hydrophobic patch serves to orient the ribose to facilitate nucleophilic attack by phosphate and subsequent inversion at C(1').
A Sw g Gate Controls Access to the Active Site. The initial electron density for PNP was weak and poorly defined near residues 241-260 (16), indicating high thermal motion for these residues. X-ray analysis of many complexes of PNP with substrates or inhibitors has now confirmed that these residues form a gate that opens during substrate binding to accommodate the substrate or a competitive inhibitor. The maximum movement after substrate or inhibitor binding occurs at His-257, which is displaced outward by several angstroms. The gate is anchored near the central (-sheet at one end and near the C-terminal helix at the other end. The gate movement is complex, apparently involving a helical transformation near residues 257-261. Consequently, initial inhibitor modeling attempts using the native PNP structure were far less successful than subsequent analyses using coordinates for the guanine-PNP complex.
Previously Known PNP Inhibitors. Prior to our studies, several PNP inhibitors had been reported with K1 values of 10-6-10-7 including 8-aminoguanine (21), 9-benzyl-8-aminoguanine (22) , and 5'-iodo-9-deazainosine (23) . Acyclovir diphosphate (24) had a Ki value near 10-8 if assayed at 1 mM phosphate rather than the more frequently used value of 50 mM. During our studies, the synthesis of 8-amino-9-(2-thienylmethyl)guanine (K1, 6 .7 x 10-8 M) was reported (25) .
Complexes of these compounds bound to PNP, which were analyzed by x-ray crystallography, are illustrated in Fig. 4 . The most important findings were the following: (i) 8-amino substituents enhance binding ofguanines by forming hydrogen bonds with Thr-242 and possibly the carbonyl oxygen atom of Ala-116, (it) 9-deaza analogs acquire potency through donation of a hydrogen bond to Asn-243, (jii) substitution by hydrophobic groups at the 9-position of a purine enhances binding through interaction with the hydrophobic region in the ribose binding site, (iv) acyclovir diphosphate is a multisubstrate inhibitor in which the acyclic spacer between N(9) of the purine and the phosphate is optimal for accommodating the two binding sites, and (v) additional binding affinity in acyclovir diphosphate may result from a hydrogen bond between the a-phosphate and Tyr-88 and from the interaction of the ethylene spacer and the hydrophobic region. Based on these results, a number of compounds were proposed that incorporated these and other features predicted to enhance inhibitor binding. between the purine base and the aromatic substituent appears to be a single methylene group.
Inhibitors with cyclic aliphatic substituents at N(9) were as potent as the aromatic analogs discussed above with the aliphatic substituents occupying the same general volume as the aromatic groups ( Table 1) . As with the aromatic series, the optimum spacer was one carbon atom. X-ray analysis of the PNP complex of 9-cyclohexyl-9-deazaguanine and the complex of 9-cyclohexylmethyl-9-deazaguanine showed the surprising result that the two cyclohexyl groups occupy approximately the same volume and the 9-deazapurine of the cyclohexyl analog is shifted in order to accommodate the nonoptimal fit to the active site.
Inhibitor Potency Is Dependent on Phosphate Concentration for a Wide Variety of Compounds. Previously, Tuttle and Krenitsky (24) established that the Ki value for acyclovir diphosphate was larger at 50 mM phosphate (standard assay conditions) than at 1 mM phosphate (cellular conditions) (27) . This result can be explained by competition between the distal phosphate group and inorganic phosphate for the phosphate binding site. During our crystallographic analysis of certain PNP-inhibitor complexes, we discovered significant displacements of the inhibitors in the active site that appeared to result from close contacts between the inhibitor and a sulfate ion that occupies the phosphate binding site. Therefore, we assayed these and other PNP inhibitors at both 1 mM and 50 mM phosphate. These results, summarized in Table 1 , show that the IC50(50 mM) is equal to or larger than the IC50(1 mM), in some cases by as much as 100-fold. The ratio and the dimension of the 9-substituent show some correlation. Some compounds, such as 8-aminoguanosine and 8-amino-9-(2-thienylmethyl)guanine, show no difference. In the case of nucleosides, the result may be due to a hydrogen bond between the phosphate and 0(3'). Since the concentration of phosphate in intact cells is =4 mM, we routinely used this assay condition for all PNP inhibitors.
8-Amino-9-deazaguanine Analogs Are Poor Inhibitors. Both 8-aminoguanine analogs and 9-deazaguanine analogs are good inhibitors of PNP; however, the first 8-amino-9-deazapurine analog prepared was a relatively poor PNP inhibitor. To explain this poor binding, we undertook crystallographic analysis of PNP complexes with four compounds having a 9-thienylmethyl substituent but with the bases being guanine, 8-aminoguanine, 9-deazaguanine, and 8-amino-9-deazaguanine. The results of the x-ray analysis are summarized in Fig. 5 . These data showed one binding mode for compounds that accept a hydrogen bond at N(7) and another for compounds that have a hydrogen bond donor at N(7). In both types of binding, a hydrogen bond is formed between N(7) and Asn-243. The 8-aminoguanine analogs make use of the Thr-242 side chain to form an additional hydrogen bond and to improve binding affinity. When N(7) has an attached hydrogen atom, Asn-243 undergoes a shift that is clearly seen in difference Fourier maps and is probably caused by the formation ofthe highly favorable N(7)-H -O hydrogen bond. A concomitant shift by Thr-242 results in its inability to hydrogen bond to 8-amino substituents. Furthermore, the overall conformational change causes the y-carbon of Thr-242 to approach the 8-position of the purine, thereby generating a hydrophobic environment for the 8-amino group and causing a decrease in binding affinity. Table  2 lists IC50 values for several PNP inhibitors, which exhibit this striking phenomenon.
Branching at the Benzylic Carbon Atom Allows for Optimum Binding of Multisubstrate Inhibitors. To take full advantage of the binding properties ofthe enzyme active site, it is necessary to design compounds that bind to all three subsites. Acyclovir diphosphate, although not membrane permeable and subject Table 2 at 50 mM phosphate. Calf spleen PNP was assayed in 50 mM phosphate buffer. G, guanine; 8-AG, 8-aminoguanine; 9-DG, 9-deazaguanine; 8-A-9-DG, 8-amino-9-deazaguanine. *Human erythrocytic PNP assayed in 50 mM phosphate buffer (28) .
to extracellular metabolism, is a good example. Our results suggest that an ideal PNP inhibitor in the 9-deazapurine series would contain a bulky hydrophobic group and a substituent with affinity for the phosphate site interlinked by spacers with optimum lengths. Crystallographic and modeling studies suggested a single atom as the optimal spacer between the purine base and hydrophobic group, while modeling studies using coordinates from the native enzyme suggested that a two-to four-atom spacer should link the hydrophobic group to a group having affinity for the phosphate binding site. Such a compound (structure 1) with a four-atom spacer from the ortho position of a benzyl group to a phosphonate group was a surprisingly poor PNP inhibitor. Subsequent crystallographic analysis revealed that the plane of the aromatic ring had rotated -90°in order to accommodate the long spacer. More sophisticated modeling studies using coordinates from the guanine-PNP complex and Monte Carlo/energy minimization techniques predicted that a twocarbon spacer would provide a better fit while maintaining the optimum orientation of the aromatic ring. A compound (structure 2) with a two-carbon spacer was a much better inhibitor of PNP; however, it was clear from the x-ray analysis that the aromatic ring was still not able to form an ideal Herringbone packing interaction. Concurrently, compounds (structure 3) were being modeled in which the spacer to the phosphate binding site branched from the benzylic carbon, thus placing no direct restrictions on the tilt of the aromatic ring. Several compounds have now been prepared in this series and confirm the modeling studies based on the x-ray structure. One of the racemic mixtures was separated, individual IC50 values were determined, and crystallographic analysis was carried out on the enantiomers. This analysis showed that the S isomer is the potent PNP inhibitor. Fig. 6 shows an active site model of the best PNP inhibitor along with the experimental electron density. This series of compounds contains the most potent membrane-permeable inhibitors of PNP yet reported. 11 Summary ofPNP. Kinetic data for selected compounds showed that the inhibitors are competitive with respect to inosine. The approach can best be described as iterative, in which accumulated knowledge is used to produce optimized compounds. Competitive inhibitors benefit from the following features: (i) an analog purine base with hydrogen bonds to Glu-201, Thr-242, Asn-243, and/or Lys-244, (it) a bulky hydrophobic group near the ribose binding site, (ii) a substituent with affinity for the phosphate binding site, and (iv) spacers that link these groups together without perturbing the binding geometry of the individual groups. These features are exemplified in compounds such as (S)-9-[1-(3-chlorophenyl)-2-carboxyethyl]-9-deazaguanine (Table 1 , first entry), which exhibits an IC50 value of 5.9 nM.
We found that computer modeling required significant tuning in order to provide useful results. Crystallographic results were useful in testing and modifying modeling parameters. The most useful modeling results were achieved after incorporation of the conformational searching techniques described above and when the coordinates for the PNPguanine complex model were used.
Crystallographic analysis was based primarily on the results of difference Fourier maps in which the quantitative relationships between residues in the active site and the inhibitor could be characterized. During these studies, =35 PNP-inhibitor complexes were evaluated by x-ray crystallographic techniques. It is noteworthy that the resolution of the PNP model extends to only 2.8 A and that all of the difference Fourier maps were calculated at 3.2 A resolution, much lower than often considered essential for drug design. Crystallographic analysis was facilitated by the large solvent content that allowed for free diffusion of inhibitors into enzymatically active crystals (28) . During the 2.5 years ofthis project, -60 active compounds were synthesized. The large number of active compounds designed and the enhancement in inhibitor potency of nearly 2 orders of magnitude stand as proof that crystallographic and computer-assisted modeling methods are now capable ofplaying a critical role in the rapid discovery of therapeutic agents.
